Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Prevenar 13 is safe for administration to Filipinos.
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study|
- Number of participants reporting adverse events as a measure of safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
|Study Start Date:||December 2011|
|Study Completion Date:||May 2014|
|Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
|Prevenar 13 patients||
Biological: Prevenar 13
Prevenar 13 vaccine as prescribed by the physician based on approved product indication
Other Name: Pneumococcal 13-valent Conjugate Vaccine (13vPnC)
Filipino patients prescribed and administered with the vaccine will be monitored for safety Patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01396434
Show 121 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|